X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (711) 711
humans (698) 698
melanoma (491) 491
proto-oncogene proteins b-raf - genetics (427) 427
mutation (370) 370
proto-oncogene proteins b-raf - antagonists & inhibitors (335) 335
oncology (319) 319
cancer (315) 315
melanoma - drug therapy (313) 313
braf (271) 271
cell line, tumor (261) 261
melanoma - genetics (253) 253
animals (230) 230
proto-oncogene proteins b-raf - metabolism (215) 215
metastatic melanoma (207) 207
vemurafenib (206) 206
melanoma - pathology (203) 203
protein kinase inhibitors - pharmacology (183) 183
b-raf (176) 176
sulfonamides - pharmacology (176) 176
indoles - pharmacology (170) 170
cell biology (163) 163
female (157) 157
kinases (156) 156
antineoplastic agents - pharmacology (154) 154
mice (147) 147
acquired-resistance (143) 143
article (143) 143
mutations (141) 141
antineoplastic agents - therapeutic use (139) 139
research (139) 139
neoplasms (137) 137
male (134) 134
tumors (134) 134
genetic aspects (132) 132
metastasis (131) 131
care and treatment (130) 130
gene mutations (129) 129
melanoma - metabolism (120) 120
signal transduction (116) 116
activation (112) 112
protein kinase inhibitors - therapeutic use (112) 112
skin neoplasms - drug therapy (112) 112
resistance (111) 111
biochemistry & molecular biology (105) 105
health aspects (102) 102
sulfonamides - therapeutic use (101) 101
indoles - therapeutic use (100) 100
middle aged (100) 100
drug resistance (98) 98
apoptosis (97) 97
skin neoplasms - genetics (97) 97
pathway (94) 94
drug resistance, neoplasm (93) 93
dermatology (92) 92
proteins (91) 91
malignant-melanoma (90) 90
raf (87) 87
map kinase signaling system - drug effects (86) 86
signal transduction - drug effects (86) 86
skin neoplasms - pathology (84) 84
survival (84) 84
cell proliferation - drug effects (83) 83
open-label (81) 81
analysis (80) 80
adult (78) 78
drug therapy (78) 78
phosphorylation (78) 78
aged (76) 76
inhibitors (76) 76
multidisciplinary sciences (74) 74
drug resistance, neoplasm - drug effects (73) 73
inhibition (73) 73
kinase (73) 73
plx4032 (73) 73
cells (71) 71
pharmacology & pharmacy (71) 71
improved survival (70) 70
melanoma - enzymology (69) 69
skin cancer (69) 69
therapy (69) 69
raf inhibitors (67) 67
xenograft model antitumor assays (67) 67
molecular targeted therapy (64) 64
dabrafenib (63) 63
drug resistance, neoplasm - genetics (63) 63
map kinase (63) 63
chemotherapy (62) 62
medicine (62) 62
digestive system diseases (60) 60
targeted therapy (60) 60
endocrine system diseases (59) 59
apoptosis - drug effects (58) 58
development and progression (58) 58
expression (58) 58
pathology (57) 57
neoplasms - drug therapy (55) 55
extracellular signal-regulated kinase (54) 54
mek (54) 54
research article (54) 54
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2010, Volume 107, Issue 33, pp. 14903 - 14908
Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is suppressed by MAPK/ERK kinase (MEK)... 
Tumor cell line | Phosphorylation | Cell growth | Negative feedback | Genes | Cell lines | Melanoma | Genetic mutation | Tumors | Cancer | LUNG-CANCER | APOPTOSIS | KINASE KINASE-1/2 INHIBITOR | ACTIVATION | PATHWAY | MULTIDISCIPLINARY SCIENCES | IN-VIVO | B-RAF | MUTATIONS | MEK INHIBITORS | ADVANCED CANCERS | Diphenylamine - pharmacology | Oligonucleotide Array Sequence Analysis | Apoptosis - drug effects | Humans | Gene Expression Profiling | Extracellular Signal-Regulated MAP Kinases - metabolism | Diphenylamine - analogs & derivatives | Mitogen-Activated Protein Kinase Kinases - metabolism | Indoles - pharmacology | Benzamides - pharmacology | G1 Phase - genetics | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Proto-Oncogene Proteins B-raf - metabolism | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Reverse Transcriptase Polymerase Chain Reaction | Sulfonamides - pharmacology | Blotting, Western | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Cell Proliferation - drug effects | Mutation | Amino Acid Substitution | Cell proliferation | Development and progression | Cellular signal transduction | Genetic aspects | Pharmacology | Research | Drug therapy | Proteins | Signal transduction | Kinases | Gene expression | Cells | Index Medicus | Biological Sciences
Journal Article
JOURNAL OF TRANSLATIONAL MEDICINE, ISSN 1479-5876, 04/2010, Volume 8
Blocking oncogenic signaling induced by the BRAF(V600E) mutation is a promising approach for melanoma treatment. We tested the anti-tumor effects of a specific... 
TARGETED THERAPY | MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | MECHANISM | GENE | PATHWAY | KINASE | RESISTANCE | BRAF | B-RAF | HUMAN CANCER
Journal Article
Journal Article
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ISSN 0006-291X, 01/2011, Volume 404, Issue 4, pp. 958 - 962
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600E), as a result of the BRAF(T1799A) mutation, plays a... 
BASES | PLX4032 | BIOCHEMISTRY & MOLECULAR BIOLOGY | KINASE | BRAF inhibitor | PATHOGENIC ROLE | BRAF mutation | Genetic-dependent therapy | Thyroid cancer | BIOPHYSICS | CLINICAL-IMPLICATIONS | RAF INHIBITORS | RG7204 | MUTANTS | INHIBITION | THERAPY | PHOSPHORYLATION | SENSITIVITY | THYROID | CELL PROLIFERATION | MELANOMAS | MUTATIONS | 60 APPLIED LIFE SCIENCES
Journal Article
by Liu, RX and Liu, DX and Xing, MZ
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, ISSN 0021-972X, 02/2012, Volume 97, Issue 2, pp. E173 - E182
Purpose: The purpose of the study was to explore optimal combinations of currently actively developed drugs for dually targeting the Ras -> Raf -> MAPK kinase... 
CARCINOMA-CELLS | PHOSPHATIDYLINOSITOL 3-KINASE/AKT | IN-VITRO | BRAF MUTATION | PATHWAY | ENDOCRINOLOGY & METABOLISM | CLINICAL-IMPLICATIONS | PHASE-II | MELANOMA-CELLS | PATHOGENIC ROLE | GENETIC ALTERATIONS | Heterocyclic Compounds, 3-Ring - pharmacology | Glutamic Acid - genetics | Humans | Oncogene Protein v-akt - antagonists & inhibitors | Phosphorylcholine - analogs & derivatives | Phosphorylcholine - administration & dosage | Indoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Benzimidazoles - administration & dosage | Phosphorylcholine - pharmacology | Indoles - pharmacology | Tumor Cells, Cultured | Carcinoma - pathology | Drug Evaluation, Preclinical | Mutant Proteins - antagonists & inhibitors | Carcinoma - drug therapy | Sulfonamides - antagonists & inhibitors | Mutant Proteins - genetics | Down-Regulation - drug effects | Sulfonamides - pharmacology | Benzimidazoles - antagonists & inhibitors | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Drug Antagonism | Thyroid Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - genetics | Heterocyclic Compounds, 3-Ring - administration & dosage | Phosphorylcholine - adverse effects | Benzimidazoles - pharmacology | Valine - genetics | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Indoles - antagonists & inhibitors | Sulfonamides - administration & dosage | Thyroid Neoplasms - pathology | Index Medicus | Abridged Index Medicus
Journal Article
MATRIX BIOLOGY, ISSN 0945-053X, 10/2015, Volume 48, pp. 66 - 77
Vertical growth phase (VGP) melanoma is frequently metastatic, a process mediated by changes in gene expression, which are directed by signal transduction... 
Human melanoma | SURVIVAL | TGF-BETA | Murine melanoma | BIOCHEMISTRY & MOLECULAR BIOLOGY | BRAF | IL-8 | CELL BIOLOGY | Vemurafenib | INVASION | MMP-1 | MATRIX METALLOPROTEINASE-1 | GROWTH | STROMAL FIBROBLASTS | TGF beta | pERK | EXPRESSION | PROGRESSION | ras Proteins - genetics | Mitogen-Activated Protein Kinase Kinases - genetics | Skin Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | ras Proteins - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | raf Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - genetics | MAP Kinase Signaling System | Mitogen-Activated Protein Kinase Kinases - metabolism | Collagen Type I - genetics | Melanoma - genetics | Indoles - pharmacology | Antineoplastic Agents - pharmacology | raf Kinases - genetics | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Skin Neoplasms - pathology | Collagen Type I - metabolism | Melanoma - pathology | Sulfonamides - pharmacology | Skin Neoplasms - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Collagen Type I - agonists | Transforming Growth Factor beta - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Cell Line, Tumor | Mice | Mutation | Transforming Growth Factor beta - metabolism | Index Medicus
Journal Article
The American Journal of the Medical Sciences, ISSN 0002-9629, 2013, Volume 346, Issue 6, pp. 494 - 498
Journal Article
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 8, pp. 707 - 714
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 07/2010, Volume 70, Issue 13, pp. 5518 - 5527
The BRAF(V600E) mutation is common in several human cancers, especially melanoma. RG7204 (PLX4032) is a small-molecule inhibitor of BRAF(V600E) kinase activity... 
ONCOGENE | EFFICACY | ONCOLOGY | BRAF | B-RAF | MUTATIONS | TUMORS | RAF/MEK/ERK PATHWAY | KINASES
Journal Article
Journal of Molecular Diagnostics, The, ISSN 1525-1578, 2013, Volume 15, Issue 2, pp. 220 - 226
The US Food and Drug Administration (FDA) approved vemurafenib to treat patients with metastatic melanoma harboring the BRAF c.1799T>A (p.V600E) mutation.... 
Pathology | METASTATIC MELANOMA | NRAS | PYROSEQUENCING ASSAY | GENE | PERFORMANCE | CUTANEOUS MELANOMA | KIT | MALIGNANT-MELANOMA | PATHOLOGY | INHIBITOR PLX4032 | VEMURAFENIB | Melanoma - diagnosis | Exons | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Base Sequence | Humans | Mutation Rate | Retrospective Studies | Mutation | Index Medicus
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 07/2011, Volume 8, Issue 7, pp. 426 - 433
Journal Article